Amicus' market momentum stalls after Galafold approval

14 August 2018

Shares in rare disease specialist Amicus Therapeutics (Nasdaq: FOLD) unsurprisingly closed up on Friday following the approval of its Fabry disease drug Galafold (migalastat), but it was a different story on Monday.

The New Jersey-based biotech dipped nearly 7% to more than cancel out Friday’s gains and raise questions as to why investors had suddenly gone cold on Amicus.

One development was news on Amicus’ proposed pricing for Galafold, which is the first oral drug to win US approval for Fabry disease and the first to be approved for the rare condition in more than 15 years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK